RESERPINE Drug Patent Profile
✉ Email this page to a colleague
When do Reserpine patents expire, and when can generic versions of Reserpine launch?
Reserpine is a drug marketed by Barr, Bell Pharma, Bundy, Cycle, Elkins Sinn, Everylife, Halsey, Hikma Intl Pharms, Impax Labs, Ivax Sub Teva Pharms, Marshall Pharma, Mk Labs, Mylan, Pharmavite, Purepac Pharm, Pvt Form, Rexall, Sandoz, Solvay, Tablicaps, Teva, Valeant Pharm Intl, Watson Labs, Whiteworth Town Plsn, West Ward, Ivax Pharms, Par Pharm, Sun Pharm Industries, and Lederle. and is included in forty-one NDAs.
The generic ingredient in RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RESERPINE?
- What are the global sales for RESERPINE?
- What is Average Wholesale Price for RESERPINE?
Summary for RESERPINE
| US Patents: | 0 |
| Applicants: | 29 |
| NDAs: | 41 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 13 |
| Patent Applications: | 1,210 |
| DailyMed Link: | RESERPINE at DailyMed |
Recent Clinical Trials for RESERPINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mansoura University | Phase 4 |
| Mayo Clinic | Phase 1 |
| University of Alabama at Birmingham | Phase 2 |
Medical Subject Heading (MeSH) Categories for RESERPINE
Anatomical Therapeutic Chemical (ATC) Classes for RESERPINE
US Patents and Regulatory Information for RESERPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | RESERPINE | reserpine | TABLET;ORAL | 089020-001 | Mar 7, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pvt Form | RESERPINE | reserpine | TABLET;ORAL | 086117-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Whiteworth Town Plsn | RESERPINE | reserpine | TABLET;ORAL | 080723-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | hydralazine hydrochloride; hydrochlorothiazide; reserpine | TABLET;ORAL | 085549-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | RESERPINE | reserpine | TABLET;ORAL | 080679-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Whiteworth Town Plsn | RESERPINE | reserpine | TABLET;ORAL | 080723-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
